Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Prodrugs01:30

Prodrugs

2.6K
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
2.6K
Drug Biotransformation: Overview01:16

Drug Biotransformation: Overview

2.4K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
2.4K
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

278
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
278
Preclinical Development: Overview01:28

Preclinical Development: Overview

4.4K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.4K
Drug Discovery: Overview01:26

Drug Discovery: Overview

7.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.9K
Bioequivalence: Overview01:16

Bioequivalence: Overview

1.0K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Total Synthesis and Antibacterial Evaluation of (-)- and (+)-<i>epi</i>-Perrottetinene.

ACS infectious diseases·2026
Same author

One-pot click chemistry using hydrazine as an azide surrogate: easy access to 1,2,3-triazole functionalities.

Organic & biomolecular chemistry·2026
Same author

Development of Benzimidazole-Based BZ-30 as an Orally Bioavailable Broad-Spectrum Inhibitor of SARS-CoV-2.

Journal of medicinal chemistry·2026
Same author

Correction to "Design of Novel 3-Pyrimidinylazaindole CDK2/9 Inhibitors with Potent In Vitro and In Vivo Antitumor Efficacy in a Triple-Negative Breast Cancer Model".

Journal of medicinal chemistry·2026
Same author

Crocetin Impairs the Cytochrome P450 Epoxygenase Pathway toward Potentiating the Therapeutic Efficacy of Paclitaxel in Metastatic Breast Cancer.

ACS omega·2025
Same author

Discovery of 2-(4-Ureido-piperidin-1-yl)-4-morpholinothieno [3,2-D] Pyrimidines as Orally Bioavailable Phosphoinositide-3-Kinase Inhibitors with <i>In Vitro</i> and <i>In Vivo</i> Antitumor Efficacy in Triple-Negative Breast Cancer.

Journal of medicinal chemistry·2025

Related Experiment Video

Updated: Jul 3, 2025

Ultrasonic-Assisted Extraction of Cannabidiolic Acid from Cannabis Biomass
05:46

Ultrasonic-Assisted Extraction of Cannabidiolic Acid from Cannabis Biomass

Published on: May 27, 2022

6.1K

Cannabidiol-Based Prodrugs: Synthesis and Bioevaluation.

Pankaj Singh Cham1,2, Pankul Kotwal3,2, Kuhu Sharma3,2

  • 1Natural Product & Medicinal Chemistry Division, CSIR-Indian Institute of Integrative Medicine (CSIR-IIIM), Canal Road, Jammu 180001, India.

ACS Medicinal Chemistry Letters
|February 14, 2024
PubMed
Summary

Researchers developed novel cannabidiol (CBD) prodrugs to enhance solubility and oral bioavailability for epilepsy treatment. Morpholinyl CBD prodrugs 3a and 3aa demonstrated improved properties and therapeutic efficacy, offering a promising alternative to high-dose CBD.

More Related Videos

Synthesis of a Deuterated Standard for the Quantification of 2-Arachidonoylglycerol in Caenorhabditis elegans
14:25

Synthesis of a Deuterated Standard for the Quantification of 2-Arachidonoylglycerol in Caenorhabditis elegans

Published on: September 21, 2019

7.3K
Technical Aspect of the Automated Synthesis and Real-Time Kinetic Evaluation of [11C]SNAP-7941
09:50

Technical Aspect of the Automated Synthesis and Real-Time Kinetic Evaluation of [11C]SNAP-7941

Published on: April 28, 2019

7.6K

Related Experiment Videos

Last Updated: Jul 3, 2025

Ultrasonic-Assisted Extraction of Cannabidiolic Acid from Cannabis Biomass
05:46

Ultrasonic-Assisted Extraction of Cannabidiolic Acid from Cannabis Biomass

Published on: May 27, 2022

6.1K
Synthesis of a Deuterated Standard for the Quantification of 2-Arachidonoylglycerol in Caenorhabditis elegans
14:25

Synthesis of a Deuterated Standard for the Quantification of 2-Arachidonoylglycerol in Caenorhabditis elegans

Published on: September 21, 2019

7.3K
Technical Aspect of the Automated Synthesis and Real-Time Kinetic Evaluation of [11C]SNAP-7941
09:50

Technical Aspect of the Automated Synthesis and Real-Time Kinetic Evaluation of [11C]SNAP-7941

Published on: April 28, 2019

7.6K

Area of Science:

  • Medicinal Chemistry
  • Pharmacology
  • Drug Discovery

Background:

  • Cannabidiol (CBD) is FDA-approved for refractory epilepsy but suffers from poor aqueous solubility and oral bioavailability.
  • High doses of CBD are often required, necessitating the development of improved drug delivery systems.

Purpose of the Study:

  • To synthesize and evaluate novel CBD-based prodrugs with enhanced solubility and oral bioavailability.
  • To address the limitations of conventional CBD administration for epilepsy treatment.

Main Methods:

  • Synthesis of various CBD-based prodrugs.
  • In vitro and ex vivo assays for solubility, chemical stability, and release kinetics.
  • In vivo pharmacokinetic and efficacy studies in animal models.

Main Results:

  • Morpholinyl CBD prodrugs (3a and 3aa) exhibited favorable release profiles, stability, and solubility.
  • Prodrug candidate 3aa demonstrated superior therapeutic efficacy compared to other tested prodrugs.
  • Improved pharmacokinetic profiles and oral exposure were observed for the developed prodrugs.

Conclusions:

  • CBD-based prodrugs, particularly morpholinyl derivatives like 3aa, offer a promising strategy to overcome CBD's poor solubility and bioavailability.
  • These prodrugs represent potential therapeutic agents for epilepsy with improved physicochemical properties and oral exposure.